This company has been marked as potentially delisted and may not be actively trading.

Procaps Group (PROC) Competitors

PROC vs. CADL, LRMR, CTNM, EPRX, and CGC

Should you be buying Procaps Group stock or one of its competitors? The main competitors of Procaps Group include Candel Therapeutics (CADL), Larimar Therapeutics (LRMR), Contineum Therapeutics (CTNM), Eupraxia Pharmaceuticals (EPRX), and Canopy Growth (CGC). These companies are all part of the "pharmaceutical products" industry.

How does Procaps Group compare to Candel Therapeutics?

Candel Therapeutics (NASDAQ:CADL) and Procaps Group (NASDAQ:PROC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

: 13.9% of Candel Therapeutics shares are owned by institutional investors. 16.6% of Candel Therapeutics shares are owned by insiders. Comparatively, 19.9% of Procaps Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
: Candel Therapeutics has a beta of -0.59, suggesting that its stock price is 159% less volatile than the S&P 500. Comparatively, Procaps Group has a beta of -0.05, suggesting that its stock price is 105% less volatile than the S&P 500.
: Procaps Group's return on equity of 0.00% beat Candel Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Candel Therapeutics N/A -51.44% -36.31%
Procaps Group N/A N/A N/A
: In the previous week, Candel Therapeutics had 8 more articles in the media than Procaps Group. MarketBeat recorded 8 mentions for Candel Therapeutics and 0 mentions for Procaps Group. Procaps Group's average media sentiment score of 0.00 beat Candel Therapeutics' score of -0.05 indicating that Procaps Group is being referred to more favorably in the news media.
Company Overall Sentiment
Candel Therapeutics Neutral
Procaps Group Neutral
: Candel Therapeutics currently has a consensus price target of $18.00, indicating a potential upside of 134.68%. Given Candel Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Candel Therapeutics is more favorable than Procaps Group.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Candel Therapeutics
2 Sell rating(s)
1 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.44
Procaps Group
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Procaps Group has higher revenue and earnings than Candel Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Candel Therapeutics N/A N/A -$38.18M -$0.71 N/A
Procaps Group $409.92M 0.28 $42.54M N/A N/A

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-51.44%	-36.31%
Procaps Group	N/A	N/A	N/A

Company	Overall Sentiment
Candel Therapeutics	Neutral
Procaps Group	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44
Procaps Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.71	N/A
Procaps Group	$409.92M	0.28	$42.54M	N/A	N/A

Summary

Procaps Group beats Candel Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Procaps Group compare to Larimar Therapeutics?

Procaps Group (NASDAQ:PROC) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

: Larimar Therapeutics has a consensus price target of $16.50, indicating a potential upside of 311.47%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Larimar Therapeutics is more favorable than Procaps Group.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Procaps Group
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Larimar Therapeutics
1 Sell rating(s)

0 Hold rating(s)

6 Buy rating(s)

3 Strong Buy rating(s)
3.10
: Procaps Group has a beta of -0.05, suggesting that its stock price is 105% less volatile than the S&P 500. Comparatively, Larimar Therapeutics has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500.
: Procaps Group's return on equity of 0.00% beat Larimar Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Procaps Group N/A N/A N/A
Larimar Therapeutics N/A -137.70% -101.43%
: In the previous week, Larimar Therapeutics had 4 more articles in the media than Procaps Group. MarketBeat recorded 4 mentions for Larimar Therapeutics and 0 mentions for Procaps Group. Larimar Therapeutics' average media sentiment score of 0.66 beat Procaps Group's score of 0.00 indicating that Larimar Therapeutics is being referred to more favorably in the news media.
Company Overall Sentiment
Procaps Group Neutral
Larimar Therapeutics Positive
: 91.9% of Larimar Therapeutics shares are held by institutional investors. 19.9% of Procaps Group shares are held by company insiders. Comparatively, 4.5% of Larimar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
: Procaps Group has higher revenue and earnings than Larimar Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Procaps Group $409.92M 0.28 $42.54M N/A N/A
Larimar Therapeutics N/A N/A -$165.67M -$2.21 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Procaps Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10

Company	Net Margins	Return on Equity	Return on Assets
Procaps Group	N/A	N/A	N/A
Larimar Therapeutics	N/A	-137.70%	-101.43%

Company	Overall Sentiment
Procaps Group	Neutral
Larimar Therapeutics	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Procaps Group	$409.92M	0.28	$42.54M	N/A	N/A
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.21	N/A

Summary

Larimar Therapeutics beats Procaps Group on 8 of the 13 factors compared between the two stocks.

How does Procaps Group compare to Contineum Therapeutics?

Contineum Therapeutics (NASDAQ:CTNM) and Procaps Group (NASDAQ:PROC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

: Contineum Therapeutics presently has a consensus price target of $19.50, indicating a potential upside of 35.51%. Given Contineum Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Contineum Therapeutics is more favorable than Procaps Group.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Contineum Therapeutics
1 Sell rating(s)
1 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.50
Procaps Group
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Contineum Therapeutics has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Procaps Group has a beta of -0.05, indicating that its stock price is 105% less volatile than the S&P 500.
: Procaps Group's return on equity of 0.00% beat Contineum Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Contineum Therapeutics N/A -30.08% -28.27%
Procaps Group N/A N/A N/A
: In the previous week, Contineum Therapeutics had 6 more articles in the media than Procaps Group. MarketBeat recorded 6 mentions for Contineum Therapeutics and 0 mentions for Procaps Group. Contineum Therapeutics' average media sentiment score of 0.38 beat Procaps Group's score of 0.00 indicating that Contineum Therapeutics is being referred to more favorably in the media.
Company Overall Sentiment
Contineum Therapeutics Neutral
Procaps Group Neutral
: Procaps Group has higher revenue and earnings than Contineum Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Contineum Therapeutics $50M 10.75 -$59.98M -$2.18 N/A
Procaps Group $409.92M 0.28 $42.54M N/A N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Procaps Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-30.08%	-28.27%
Procaps Group	N/A	N/A	N/A

Company	Overall Sentiment
Contineum Therapeutics	Neutral
Procaps Group	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	$50M	10.75	-$59.98M	-$2.18	N/A
Procaps Group	$409.92M	0.28	$42.54M	N/A	N/A

Summary

Contineum Therapeutics beats Procaps Group on 7 of the 11 factors compared between the two stocks.

How does Procaps Group compare to Eupraxia Pharmaceuticals?

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Procaps Group (NASDAQ:PROC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

: Eupraxia Pharmaceuticals presently has a consensus price target of $15.00, indicating a potential upside of 106.33%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Eupraxia Pharmaceuticals is more favorable than Procaps Group.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eupraxia Pharmaceuticals
2 Sell rating(s)
0 Hold rating(s)

4 Buy rating(s)

2 Strong Buy rating(s)
2.75
Procaps Group
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Eupraxia Pharmaceuticals has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, Procaps Group has a beta of -0.05, indicating that its stock price is 105% less volatile than the S&P 500.
: Procaps Group's return on equity of 0.00% beat Eupraxia Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Eupraxia Pharmaceuticals N/A -167.68% -66.72%
Procaps Group N/A N/A N/A
: In the previous week, Eupraxia Pharmaceuticals had 6 more articles in the media than Procaps Group. MarketBeat recorded 6 mentions for Eupraxia Pharmaceuticals and 0 mentions for Procaps Group. Eupraxia Pharmaceuticals' average media sentiment score of 0.41 beat Procaps Group's score of 0.00 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media.
Company Overall Sentiment
Eupraxia Pharmaceuticals Neutral
Procaps Group Neutral
: Procaps Group has higher revenue and earnings than Eupraxia Pharmaceuticals.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Eupraxia Pharmaceuticals N/A N/A -$38.58M -$1.03 N/A
Procaps Group $409.92M 0.28 $42.54M N/A N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.75
Procaps Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-167.68%	-66.72%
Procaps Group	N/A	N/A	N/A

Company	Overall Sentiment
Eupraxia Pharmaceuticals	Neutral
Procaps Group	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.03	N/A
Procaps Group	$409.92M	0.28	$42.54M	N/A	N/A

Summary

Eupraxia Pharmaceuticals beats Procaps Group on 7 of the 11 factors compared between the two stocks.

How does Procaps Group compare to Canopy Growth?

Canopy Growth (NASDAQ:CGC) and Procaps Group (NASDAQ:PROC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

: Procaps Group has a net margin of 0.00% compared to Canopy Growth's net margin of -94.39%. Procaps Group's return on equity of 0.00% beat Canopy Growth's return on equity.
Company Net Margins Return on Equity Return on Assets
Canopy Growth -94.39% -46.85% -28.95%
Procaps Group N/A N/A N/A
: In the previous week, Canopy Growth had 6 more articles in the media than Procaps Group. MarketBeat recorded 6 mentions for Canopy Growth and 0 mentions for Procaps Group. Canopy Growth's average media sentiment score of 0.99 beat Procaps Group's score of 0.00 indicating that Canopy Growth is being referred to more favorably in the media.
Company Overall Sentiment
Canopy Growth Positive
Procaps Group Neutral
: Canopy Growth has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500. Comparatively, Procaps Group has a beta of -0.05, suggesting that its stock price is 105% less volatile than the S&P 500.
: Procaps Group has higher revenue and earnings than Canopy Growth.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Canopy Growth $225.65M 1.93 -$429.86M -$1.30 N/A
Procaps Group $409.92M 0.28 $42.54M N/A N/A
: 3.3% of Canopy Growth shares are owned by institutional investors. 0.2% of Canopy Growth shares are owned by company insiders. Comparatively, 19.9% of Procaps Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Canopy Growth
2 Sell rating(s)
3 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.00
Procaps Group
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00

Company	Net Margins	Return on Equity	Return on Assets
Canopy Growth	-94.39%	-46.85%	-28.95%
Procaps Group	N/A	N/A	N/A

Company	Overall Sentiment
Canopy Growth	Positive
Procaps Group	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canopy Growth	$225.65M	1.93	-$429.86M	-$1.30	N/A
Procaps Group	$409.92M	0.28	$42.54M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Canopy Growth	2 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Procaps Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Canopy Growth beats Procaps Group on 7 of the 13 factors compared between the two stocks.

Get Procaps Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PROC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PROC vs. The Competition

Export

Metric	Procaps Group	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$113.95M	$883.41M	$6.25B	$11.77B
Dividend Yield	N/A	4.84%	2.74%	5.26%
P/E Ratio	N/A	1.71	29.25	27.07
Price / Sales	0.28	119.23	504.68	73.43
Price / Cash	N/A	20.07	43.30	53.90
Price / Book	N/A	7.60	9.67	6.69
Net Income	$42.54M	-$4.80M	$3.55B	$332.64M

Procaps Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PROC Procaps Group	N/A	$1.01 flat	N/A	N/A	$113.95M	$409.92M	N/A	4,900
CADL Candel Therapeutics	3.105 of 5 stars	$6.18 flat	$18.00 +191.3%	N/A	$452.67M	N/A	N/A	60	News Coverage Upcoming Earnings
LRMR Larimar Therapeutics	4.065 of 5 stars	$4.06 -6.5%	$16.50 +306.4%	N/A	$450.85M	N/A	N/A	30	Upcoming Earnings
CTNM Contineum Therapeutics	1.986 of 5 stars	$12.82 +6.5%	$19.50 +52.1%	N/A	$449.53M	$50M	N/A	31	Earnings Report
EPRX Eupraxia Pharmaceuticals	2.2916 of 5 stars	$7.80 +6.3%	$15.00 +92.3%	N/A	$443.59M	N/A	N/A	29	News Coverage Upcoming Earnings Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PROC) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Procaps Group (PROC) Competitors

PROC vs. CADL, LRMR, CTNM, EPRX, and CGC

How does Procaps Group compare to Candel Therapeutics?

Summary

How does Procaps Group compare to Larimar Therapeutics?

Summary

How does Procaps Group compare to Contineum Therapeutics?

Summary

How does Procaps Group compare to Eupraxia Pharmaceuticals?

Summary

How does Procaps Group compare to Canopy Growth?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROC vs. The Competition

Procaps Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Procaps Group (PROC) Competitors

PROC vs. CADL, LRMR, CTNM, EPRX, and CGC

How does Procaps Group compare to Candel Therapeutics?

Summary

How does Procaps Group compare to Larimar Therapeutics?

Summary

How does Procaps Group compare to Contineum Therapeutics?

Summary

How does Procaps Group compare to Eupraxia Pharmaceuticals?

Summary

How does Procaps Group compare to Canopy Growth?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROC vs. The Competition

Procaps Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools